15 July 2021
\n \n \n \nThe QCovid\u00ae-powered COVID-19 Population Risk Assessment, developed by a cross-organisational team and rolled across NHS England, has won the Florence Nightingale Award for Excellence in Healthcare Data Analytics.
\n \n\n \n \n5 July 2021
\n \n \n \nThe PRINCIPLE trial has been highly commended at the Health Data Research UK Awards for the way in which patient data is utilised so participants are contacted about the trial soon after receiving a positive test result.
\n \n\n \n \n30 June 2021
\n \n \n \nGood data on Long COVID will be crucial for research into the prevalence of Long COVID, its causes and consequences, and to plan services effectively, say researchers following their analysis of 96% of electronic healthcare records in England using the OpenSAFELY platform.
\n \n\n \n \n23 June 2021
\n \n \n \nFrom today, ivermectin is being investigated in the UK as part of the Platform Randomised Trial of Treatments in the Community for Epidemic and Pandemic Illnesses (PRINCIPLE), the world\u2019s largest clinical trial of possible COVID-19 treatments for recovery at home and in other non-hospital settings.
\n \n\n \n \n21 June 2021
\n \n \n \nThere are higher proportions of ethnic minority children in England testing positive for COVID-19 than white children, with Asian children more likely to be admitted to hospital with the illness, finds an observational analysis of 2.6 million healthcare records led by Oxford University researchers.
\n \n\n \n \n20 May 2021
\n \n \n \nEach year, International Clinical Trials Day recognises the people who conduct clinical trials, giving our community a chance to say thank you for everything they do to improve public health. This year our trials unit staff are sharing what makes them proud to be part of Oxford\u2019s Primary Care Clinical Trials Unit.
\n \n\n \n \n14 May 2021
\n \n \n \n\n \n \n29 April 2021
\n \n \n \nThe first large study to report the effect of bodyweight on risk of worse outcomes from COVID-19 across the full range of body mass index (BMI) is published today in The Lancet Diabetes and Endocrinology journal.
\n \n\n \n \n16 April 2021
\n \n \n \n\n \n \n12 April 2021
\n \n \n \nInhaled budesonide, a common corticosteroid, is the world's first widely available, inexpensive drug found to shorten recovery times in COVID-19 patients aged over 50 who are treated at home and in other community settings, reports the PRINCIPLE trial in 1,779 participants. As of today, the treatment is available in UK primary care on a case-by-case basis.
\n \n\n \n \n8 April 2021
\n \n \n \nCould the antiviral favipiravir help transform COVID-19 into an illness that can be successfully treated by general practitioners?
\n \n\n \n \n2 April 2021
\n \n \n \nPeople with asthma have only a modestly increased risk of developing severe Covid-19 and requiring admission to hospital from the illness, finds an analysis of 8.3 million electronic health care records in England led by University of Oxford researchers.
\n \n\n \n \n19 March 2021
\n \n \n \nClose monitoring and evaluation as schools reopen crucial to inform ongoing policy
\n \n\n \n \n3 March 2021
\n \n \n \nFrom today, the UK\u2019s national priority platform trial of Covid-19 treatments for recovery at home launches its investigation of the gout drug colchicine, and expands for the first time to include adults of any age.
\n \n\n \n \n16 February 2021
\n \n \n \nMore people in England at high risk from Covid-19 will get priority access to vaccines thanks to new technology developed by a University of Oxford-led team of researchers that can identify those who may be most vulnerable to the virus.
\n \n\n \n \n25 January 2021
\n \n \n \nUpdate from the Chief Investigators of the Platform Randomised trial of INterventions against COVID-19 In older peoPLE (PRINCIPLE), 25 January 2021
\n \n\n \n \n15 January 2021
\n \n \n \nA new study led by the University of Oxford has found that since the first coronavirus lockdown the number of people diagnosed with bowel cancer in England has fallen sharply, with a deficit persisting up to October 2020.
\n \n\n \n \n27 November 2020
\n \n \n \nIn Covid-19, inhaled budesonide may prevent damaging inflammation, stop the virus from getting into lung cells and inhibit viral replication.
\n \n\n \n \n18 November 2020
\n \n \n \nTwo of the UK\u2019s largest pharmacy chains, LloydsPharmacy and Well Pharmacy, are tasking their branches with helping to find suitable patients for the PRINCIPLE Trial of Covid-19 treatments.
\n \n\n \n \n3 November 2020
\n \n \n \nLed by a research team in the Nuffield Department of Primary Care Health Sciences, the University of Oxford will take part in a new pilot scheme to assess the use of Lateral Flow Tests (LFTs), a new COVID-19 test designed to identify asymptomatic individuals with the virus.
\n \n\n \n \n